好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Healthcare Utilization and Inpatient/Emergency Department Costs in Adult and Pediatric Functional Neurological Disorders: a Growing Problem
General Neurology
S21 - Neuroepidemiology (3:54 PM-4:06 PM)
003

To assess inpatient and emergency department (ED) healthcare utilization in functional neurological disorders (FND) in adults and children, using large federal databases.

FND represents up to 31% of adult neurology outpatient visits, 20% of movement disorders clinics, and up to 10% of neurology inpatient admissions and are a common cause of ED presentations. Despite this, there is little cost and healthcare utilization data available for FND and no data for the pediatric population.

We utilized three large federal healthcare databases, assessing 1) all-payer inpatient hospitalizations, 2) pediatric hospitalizations, and 3) adult/pediatric ED presentations. We assessed adults age 18+ and pediatric patients age 5-17. We used a necessarily narrow and specific definition of FND, utilizing ICD9 codes 300.11 “conversion disorder” or 306.0 “musculoskeletal malfunction arising from mental factors”. Costs and healthcare utilization data for FND were compared to other common neurological disorders.

Adult/pediatric FND inpatient admissions were more frequently emergent, had shorter hospital stays but higher rates of common workup than in other neurological disorders (p<0.0001). FND had unexpectedly low inpatient psychiatric consultation rates and were less likely to be seen by physical/occupational/speech therapy. Annual inpatient charges (proxy for total costs) for adult FND in 2014 were estimated at $827,260,087, comparable with refractory epilepsy, pediatric inpatient charges in 2012 were $70,027,872, comparable with neuro-inflammatory diseases and adult/pediatric charges for ED visits in 2013 were $95,237,186. Healthcare costs for FND appear to be rising from 2009-2014.

There were high levels of inpatient and ED healthcare utilization by FND patients, comparable to other investigation-intensive and pharmacologically-demanding neurological disorders. While a likely under-estimate and not including outpatient costs, the total annual charges to the healthcare system were estimated at over $900m and concerningly, appear to be rising. These data should inform healthcare policy, given the opportunity to improve care and reduce unnecessary healthcare costs.

Authors/Disclosures
Christopher D. Stephen, MB ChB, FRCP, SM
PRESENTER
The institution of Dr. Stephen has received research support from Sanofi. Dr. Stephen has received research support from National Institutes of Health.
Codrin I. Lungu, MD, FAAN Dr. Lungu has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier, inc..
Alberto J. Espay, MD, FAAN (University of Cincinnati) Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tanabe Pharma America (formerly, Neuroderm). Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acorda. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sunovion. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Herantis Pharma. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus (formerly USWorldMeds). Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaps Dx. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bial. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NeuroDiagnostics, Inc (SYNAPS Dx). Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Intrance Medical Systems, Inc.. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Praxis Precision Medicines. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Citrus Health. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AskBio. The institution of Dr. Espay has received research support from NIH. The institution of Dr. Espay has received research support from Michael J Fox Foundation for Parkinson's Research. Dr. Espay has received intellectual property interests from a discovery or technology relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care.